Samuel C Zhang, Sungjin Kim, Jennifer Steers, Bradley Stiehl, Katrina D Silos, Giana Grigsby, Maria Oorloff, Taman Upadhaya, Robert A Vescio, David R Oveisi, Behrooz Hakimian, Katelyn M Atkins, Leslie K Ballas
{"title":"辐照骨髓量与多发性骨髓瘤患者的血液学毒性有关。","authors":"Samuel C Zhang, Sungjin Kim, Jennifer Steers, Bradley Stiehl, Katrina D Silos, Giana Grigsby, Maria Oorloff, Taman Upadhaya, Robert A Vescio, David R Oveisi, Behrooz Hakimian, Katelyn M Atkins, Leslie K Ballas","doi":"10.1016/j.ijrobp.2024.10.017","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Palliative radiation therapy (RT) is effective for multiple myeloma (MM) but may cause cytopenia. Bone marrow volume receiving 10 Gy (BMV10Gy) has been associated with hematologic toxicity (HT) in cervical cancer, but no studies have investigated this in MM. We hypothesized that absolute BMV10Gy is associated with acute HT in MM patients receiving palliative RT.</p><p><strong>Materials and methods: </strong>This single institution retrospective analysis evaluated 125 MM patients who received palliative RT between 2007 and 2023 and had ≥2 weeks of follow-up laboratory data. Laboratory values were recorded pre-RT, post-RT, and at nadir within 90 days of completing RT. Clinical HT was defined as new transfusion/growth factor, admission for HT, and/or systemic therapy pause/discontinuation. BM was defined as a bone volume within the RT field. BMV5-40Gy (cubic centimeter [cm<sup>3</sup>]) was recorded for each treatment. Logistic regressions were performed with clinical HT as the primary endpoint.</p><p><strong>Results: </strong>Around 105 (84%) patients received concurrent systemic therapy. Median BMV10Gy was 266 cm<sup>3</sup> (IQR, 157-501 cm<sup>3</sup>). Median RT equivalent dose in 2 Gy fractions was 26 Gy (IQR, 23-33 Gy). On univariable analysis, BMV5Gy, BMV10Gy, and BMV15Gy were significantly associated with clinical HT (P = .014, P = .018, P = .050, respectively), while RT equivalent dose in 2 Gy fractions dose was not (P = .997). On multivariable analysis, BMV10Gy was significantly associated with clinical HT (P = .049) after adjusting for dose, number of lesions treated, lesion location (spine, pelvis, limb, and soft tissue), and systemic therapy class. Disease course (number of prior systemic therapies) was significantly associated with clinical HT on univariable and multivariable analysis, with late relapsed/refractory patients (≥3 prior systemic therapies) having 9.6 higher odds of clinical HT compared to newly diagnosed patients (P < .001).</p><p><strong>Conclusions: </strong>To our knowledge, this is the first study to associate the volume of irradiated BM with acute HT in MM. In addition to BMV5-15Gy, number of prior relapses and systemic therapy lines were significantly associated with HT. Disease history should be evaluated, and RT field volumes were minimized for patients with poor bone marrow reserve (eg, late relapsed/refractory disease).</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Irradiated Bone Marrow Volume is Associated With Hematologic Toxicity in Patients With Multiple Myeloma.\",\"authors\":\"Samuel C Zhang, Sungjin Kim, Jennifer Steers, Bradley Stiehl, Katrina D Silos, Giana Grigsby, Maria Oorloff, Taman Upadhaya, Robert A Vescio, David R Oveisi, Behrooz Hakimian, Katelyn M Atkins, Leslie K Ballas\",\"doi\":\"10.1016/j.ijrobp.2024.10.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Palliative radiation therapy (RT) is effective for multiple myeloma (MM) but may cause cytopenia. Bone marrow volume receiving 10 Gy (BMV10Gy) has been associated with hematologic toxicity (HT) in cervical cancer, but no studies have investigated this in MM. We hypothesized that absolute BMV10Gy is associated with acute HT in MM patients receiving palliative RT.</p><p><strong>Materials and methods: </strong>This single institution retrospective analysis evaluated 125 MM patients who received palliative RT between 2007 and 2023 and had ≥2 weeks of follow-up laboratory data. Laboratory values were recorded pre-RT, post-RT, and at nadir within 90 days of completing RT. Clinical HT was defined as new transfusion/growth factor, admission for HT, and/or systemic therapy pause/discontinuation. BM was defined as a bone volume within the RT field. BMV5-40Gy (cubic centimeter [cm<sup>3</sup>]) was recorded for each treatment. Logistic regressions were performed with clinical HT as the primary endpoint.</p><p><strong>Results: </strong>Around 105 (84%) patients received concurrent systemic therapy. Median BMV10Gy was 266 cm<sup>3</sup> (IQR, 157-501 cm<sup>3</sup>). Median RT equivalent dose in 2 Gy fractions was 26 Gy (IQR, 23-33 Gy). On univariable analysis, BMV5Gy, BMV10Gy, and BMV15Gy were significantly associated with clinical HT (P = .014, P = .018, P = .050, respectively), while RT equivalent dose in 2 Gy fractions dose was not (P = .997). On multivariable analysis, BMV10Gy was significantly associated with clinical HT (P = .049) after adjusting for dose, number of lesions treated, lesion location (spine, pelvis, limb, and soft tissue), and systemic therapy class. Disease course (number of prior systemic therapies) was significantly associated with clinical HT on univariable and multivariable analysis, with late relapsed/refractory patients (≥3 prior systemic therapies) having 9.6 higher odds of clinical HT compared to newly diagnosed patients (P < .001).</p><p><strong>Conclusions: </strong>To our knowledge, this is the first study to associate the volume of irradiated BM with acute HT in MM. In addition to BMV5-15Gy, number of prior relapses and systemic therapy lines were significantly associated with HT. Disease history should be evaluated, and RT field volumes were minimized for patients with poor bone marrow reserve (eg, late relapsed/refractory disease).</p>\",\"PeriodicalId\":14215,\"journal\":{\"name\":\"International Journal of Radiation Oncology Biology Physics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.4000,\"publicationDate\":\"2024-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology Biology Physics\",\"FirstCategoryId\":\"88\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijrobp.2024.10.017\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.10.017","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Irradiated Bone Marrow Volume is Associated With Hematologic Toxicity in Patients With Multiple Myeloma.
Purpose: Palliative radiation therapy (RT) is effective for multiple myeloma (MM) but may cause cytopenia. Bone marrow volume receiving 10 Gy (BMV10Gy) has been associated with hematologic toxicity (HT) in cervical cancer, but no studies have investigated this in MM. We hypothesized that absolute BMV10Gy is associated with acute HT in MM patients receiving palliative RT.
Materials and methods: This single institution retrospective analysis evaluated 125 MM patients who received palliative RT between 2007 and 2023 and had ≥2 weeks of follow-up laboratory data. Laboratory values were recorded pre-RT, post-RT, and at nadir within 90 days of completing RT. Clinical HT was defined as new transfusion/growth factor, admission for HT, and/or systemic therapy pause/discontinuation. BM was defined as a bone volume within the RT field. BMV5-40Gy (cubic centimeter [cm3]) was recorded for each treatment. Logistic regressions were performed with clinical HT as the primary endpoint.
Results: Around 105 (84%) patients received concurrent systemic therapy. Median BMV10Gy was 266 cm3 (IQR, 157-501 cm3). Median RT equivalent dose in 2 Gy fractions was 26 Gy (IQR, 23-33 Gy). On univariable analysis, BMV5Gy, BMV10Gy, and BMV15Gy were significantly associated with clinical HT (P = .014, P = .018, P = .050, respectively), while RT equivalent dose in 2 Gy fractions dose was not (P = .997). On multivariable analysis, BMV10Gy was significantly associated with clinical HT (P = .049) after adjusting for dose, number of lesions treated, lesion location (spine, pelvis, limb, and soft tissue), and systemic therapy class. Disease course (number of prior systemic therapies) was significantly associated with clinical HT on univariable and multivariable analysis, with late relapsed/refractory patients (≥3 prior systemic therapies) having 9.6 higher odds of clinical HT compared to newly diagnosed patients (P < .001).
Conclusions: To our knowledge, this is the first study to associate the volume of irradiated BM with acute HT in MM. In addition to BMV5-15Gy, number of prior relapses and systemic therapy lines were significantly associated with HT. Disease history should be evaluated, and RT field volumes were minimized for patients with poor bone marrow reserve (eg, late relapsed/refractory disease).
期刊介绍:
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.